亚太地区发展中国家的哮喘:负担、危险因素与管理挑战
本文通过整合截至2023年2月的系统综述和叙述性综述证据,总结了发展中国家尤其是亚太地区哮喘的负担、危险因素和管理挑战。研究发现,尽管低及中低收入国家的哮喘患病率通常低于高收入国家,但其疾病负担显著更高,且存在多种危险因素和医疗保健不平等问题。作者呼吁制定针对该区域的行动蓝图以减轻哮喘负担。
要点
- 亚太地区低及中低收入国家哮喘患病率虽低但负担更重。
- 危险因素包括产前产后因素、环境、生活方式、个体特征和遗传。
- 优质防治医疗分布不均、诊断措施缺乏及新药不可及等管理挑战突出。
核心结论
- 亚太地区低及中低收入国家的哮喘负担显著高于高收入国家,需制定区域特异性行动蓝图。
研究设计与样本
- 整合截至2023年2月发表的系统综述和叙述性综述证据,聚焦亚太地区发展中国家哮喘的负担、危险因素和管理挑战。
主要发现
- 低及中低收入国家的哮喘患病率通常低于高收入国家,但负担显著更高。
- 亚太地区低及中低收入国家报告的危险因素包括产前和产后因素、环境因素、生活方式措施、个体特征和遗传。
- 优质预防和治疗卫生保健分布低且不公平、缺乏先进诊断措施、新疗法不可获得且负担不起、文化信仰和实践以及疾病表型多样使最佳哮喘控制面临挑战。
临床怎么用
- 临床应关注亚太地区低及中低收入国家哮喘患者的特殊危险因素和管理障碍,推动区域针对性策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is growing interest in the epidemiology of asthma in developing countries, especially in the Asia-Pacific Region (APR). A number of reviews have been published in this field, but a comprehensive synthesis of overall data has not been reported. Here, we summarized the burden, risk factors and challenges of asthma management in developing countries with a specific emphasis on the APR by consolidating evidence from both systematic and narrative reviews published up until February 2023. We found that although asthma prevalence in low and low-middle-income countries (LMICs) is known to be generally lower compared to high-income countries, the burden is substantially greater. Studies conducted in APR LMIC have reported a range of risk factors, including pre- and post-natal factors, environmental considerations, lifestyle measures, individual features and genetics. The low and inequitable distribution of quality preventive and curative health care, a lack of advanced diagnostic measures, non-availability and non-affordability of novel therapeutics, cultural beliefs and practices, and diverse disease phenotypes make it challenging to achieve optimal asthma control in the region. Hence, we call for the development of a region-specific blueprint for action to mitigate this challenging situation, to help reduce the burden of asthma in APR LMIC.
引用
- Yasaratne D, Idrose NS, Dharmage SC, et al. Asthma in developing countries in the Asia-Pacific Region (APR). Respirology. 2023. PMID: 37702387. doi:10.1111/resp.14590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。